A new, smaller Baxter International is to be created in a move designed to resurrect Baxter's share price. The company's board of directors has approved a plan to spin off its hospital supply business into a separate entity, leaving Baxter International to focus on the more sophisticated and profitable medical technology businesses - a strategy which Baxter management considered two years ago, but decided "it was not the right thing to do" at that time.
The streamlined Baxter International, with annual sales of around $5,000 million and led by current Baxter chairman and CEO Vernon...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?